Table 3

TEAEs reported by ≥5% of patients in either group during the comparative phase (safety population)
Adverse event Number of patients (%)
IFNβ-1a (N = 65) IFNβ-1b (N = 64)
Influenza-like illness 20 (30.8) 18 (28.1)
Headache 17 (26.2) 16 (25.0)
Injection-site reaction 18 (27.7) 9 (14.1)
Injection-site erythema 8 (12.3) 8 (12.5)
Depression 4 (6.2) 8 (12.5)
Fatigue 3 (4.6) 9 (14.1)
Urinary tract infection 7 (10.8) 5 (7.8)
Extremity pain 6 (9.2) 6 (9.4)
Nausea 7 (10.8) 3 (4.7)
Insomnia 5 (7.7) 5 (7.8)
Injection-site pain 4 (6.2) 5 (7.8)
Alanine aminotransferase increased 8 (12.3) 1 (1.6)
Back pain 4 (6.2) 4 (6.3)
Dizziness 2 (3.1) 6 (9.4)
Muscle spasms 5 (7.7) 3 (4.7)
Pain 4 (6.2) 3 (4.7)
Diarrhea 2 (3.1) 5 (7.8)
Chills 5 (7.7) 2 (3.1)
Influenza 5 (7.7) 2 (3.1)
Injection-site bruising 5 (7.7) 2 (3.1)
Serum ferritin increased 6 (9.2) 0
Liver-function test abnormal 5 (7.7) 0

IFN, interferon; TEAE, treatment-emergent adverse event.

Singer et al.

Singer et al. BMC Neurology 2012 12:154   doi:10.1186/1471-2377-12-154

Open Data